Vinorelbine i.v. 25 mg/m²

DRUG2 trials

Sponsors

Boehringer Ingelheim, Gustave Roussy, Cancer Campus, Grand Paris

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)Neoplasms

Phase 1

Afatinib and Vinorelbine in Tumours Known to Overexpress EGFR and/or HER2

CompletedNCT00906698

Boehringer IngelheimNeoplasms

Start: 2009-06-30End: 2013-01-31Updated: 2014-06-09

Phase 2

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

RecruitingNCT07001618

Gustave Roussy, Cancer Campus, Grand ParisNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2025-11-17End: 2032-09-01Target: 162Updated: 2026-04-03